Isoprenalina Tillomed (Isoprenaline Hydrochloride)

Isoprenaline is a non‑selective β‑adrenergic agonist. By binding to β1 receptors in the heart, it raises cyclic AMP levels, leading to faster depolarization and stronger contractions. Activation of β2 receptors in the lungs causes smooth‑muscle relaxation, producing bronchodilation. These combined actions support circulation and breathing during acute events.

The specific dose of Isoprenalina Tillomed is determined by the prescribing clinician based on the patient’s condition, weight, and response. Dosing regimens are individualized and adjusted according to continuous cardiac and respiratory monitoring to achieve the desired therapeutic effect while minimizing adverse reactions.

Safety data for isoprenaline in pregnancy and lactation are limited. The drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians must evaluate each case carefully and discuss uncertainties with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Isoprenaline is a non‑selective β‑agonist, affecting both β1 and β2 receptors, whereas many alternatives such as albuterol are selective for β2 receptors. This broader activity makes isoprenaline useful for cardiac stimulation as well as bronchodilation, but it also carries a higher risk of cardiac side effects compared with β2‑selective agents.

Isoprenalina Tillomed must be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Do not use the product if it appears discolored or if the seal is broken.

The drug is supplied as a sterile solution for intravenous or subcutaneous injection. Administration is performed by qualified healthcare professionals under continuous monitoring, with the dose titrated to achieve the desired heart rate or bronchodilation while observing for adverse reactions.

Serious risks include life‑threatening arrhythmias, myocardial ischemia, severe hypotension, and allergic reactions such as anaphylaxis. Prompt recognition and immediate medical intervention are essential if any of these events occur during therapy.

Patients with known hypersensitivity to isoprenaline, pheochromocytoma, uncontrolled hypertension, or severe coronary artery disease should not receive the drug. Additionally, concurrent use of beta‑blockers or other agents that antagonize beta‑adrenergic activity is contraindicated.